Xenon Pharmaceuticals (XENE) Misses Q1 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Xenon Pharmaceuticals (XENE) PT Raised to $8 at Jefferies Following New Epilepsy Asset
May 10, 2017 10:35 AM EDTJefferies raised its price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $8.00 (from $7.00) while maintaining a Buy rating. The company added a new epilepsy asset, XEN1101, to their portfolio.
TV-45070 topline results are expected mid-2017. An IND for '901 is planned for 4Q17, and... More
